Anti-human CEA MAb (Clone G15) RIA
Carcino-Embryonic Antigen is classified as a Tumor Marker. Clinical use: In colorectal cancers, helps in determining stage and prognosis (significant correlation in the last two stages of Dukes' classification). Assessment of therapeutic efficacy (post-surgery, chemotherapy, or radiation treatment). Indisputable indicator in the diagnosis of recurrences when deciding to perform early repeat surgery. In breast and lung cancers, the link between CEA levels and metastatic spread of the disease constitutes an element for assessment of a patients response to treatment. In medullary thyroid cancer, the combination of CEA and thyrocalcitonin helps to confirm diagnosis and monitor relapses. Our proprietary mouse monoclonal antibody (IgG1) is used in IVD kits and for Research purposes.